Stacy R Lindborg, Namita A Goyal, Jonathan Katz, Matthew Burford, Jenny Li, Haggai Kaspi, Natalie Abramov, Bruno Boulanger, James D Berry, Katharine Nicholson, Tahseen Mozaffar, Robert Miller, Liberty Jenkins, Robert H Baloh, Richard Lewis, Nathan P Staff, Margaret Ayo Owegi, Bob Dagher, Netta R Blondheim-Shraga, Yael Gothelf, Yossef S Levy, Ralph Kern, Revital Aricha, Anthony J Windebank, Robert Bowser, Robert H Brown, Merit E Cudkowicz
INTRODUCTION/AIMS: Biomarkers have shown promise in amyotrophic lateral sclerosis (ALS) research, but the quest for reliable biomarkers remains active. This study evaluates the effect of debamestrocel on cerebrospinal fluid (CSF) biomarkers, an exploratory endpoint. METHODS: A total of 196 participants randomly received debamestrocel or placebo. Seven CSF samples were to be collected from all participants. Forty-five biomarkers were analyzed in the overall study and by two subgroups characterized by the ALS Functional Rating Scale-Revised (ALSFRS-R)...
April 9, 2024: Muscle & Nerve